SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

By Campo R.   DeJesus E.   Bredeek U. F.   Henry K.   Khanlou H.   Logue K.   Brinson C.   Benson P.   Dau L.   Wang H.   White K.   Flaherty J.   Fralich T.   Guyer B.   Piontkowsky D.  

Clinical Infectious Diseases, Vol. 56, Iss. 11, 2013-06 ,pp. : 1637-1645

Oxford University Press

Access to resources Recommend Favorite

Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study

By  

Current HIV Research, Vol. 10, Iss. 8, 2012-01 ,pp. : 673-678

Bentham Science Publishers

Access to resources Recommend Favorite

Protease Inhibitor Monotherapy as Maintenance Regimen in Patients With HIV Infection

By  

Current HIV Research, Vol. 10, Iss. 8, 2012-01 ,pp. : 661-672

Bentham Science Publishers

Access to resources Recommend Favorite

Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study

By Monteiro Polyana   Perez Iñaki   Pich Judit   Gatell Jose Maria   Martínez Esteban  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 2, 2013-02 ,pp. : 404-408

Oxford University Press

Access to resources Recommend Favorite

Severe Impairment of Endothelial Function with the HIV-1 Protease Inhibitor Indinavir is not Mediated by Insulin Resistance in Healthy Subjects

By Dubé Michael   Gorski Jude   Shen Changyu  

Cardiovascular Toxicology, Vol. 8, Iss. 1, 2008-03 ,pp. : 15-22

Humana Press, Inc

Access to resources Recommend Favorite